switching glp 1 agonists A Comprehensive Review of the Role of GLP-1 in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure switching glp 1 agonists New

According to forecasts, the global market is poised to grow at a compound annual growth rate (CAGR) of 11.4%, increasing from US$23.8 billion in 2024 to US$50.7 billion by 2031

Beyond T2D and obesity, semaglutide was also applied for other indications such as cardiovascular disease, fatty liver, chronic kidney disease, all of which have progressed to Phase 3, expanding the influence of GLP-1RAs into more medical fields

Denosumab improves glycaemic parameters in postmenopausal osteoporosis patients with combined type 2 diabetes mellitus

Triple agonists that target GLP-1, GIP, and glucagon receptors, such as retatrutide, are also in development and have shown even greater weight loss effects in early-phase trials